Integrated traditional Chinese and western medicine treatment of coronary heart disease, hypertension, arteriosclerosis, arrhythmia, and other cardiovascular and cerebrovascular diseases, through traditional Chinese medicine, acupuncture, traditional Chinese medicine external treatment, diet, diet, exercise, sleep, and other methods to intervene in the disease, significantly improve clinical symptoms, and enhance the overall quality of life. Dr. Xu specializes in the treatment of insomnia, chronic spleen and stomach disease, chronic cough, fatigue syndrome, as well as immune-related diseases and cancer after radiotherapy and chemotherapy and other Chinese medicine conditioning.
Phone
+86 0755-83982222-70834
Profile
Vice Chairman of the Youth Committee of the Professional Committee for Promoting Blood Circulation and Removing Blood Stasis of the Chinese Association of Integrated Traditional Chinese and Western Medicine, Vice Chairman of the Professional Committee for Cardiac Rehabilitation of the Federation of Chinese Medical Associations, Secretary-General of the Expert Committee for Cardiac Rehabilitation of Integrated Traditional Chinese and Western Medicine of the Chinese Medical Doctor Association, Vice Chairman of the Professional Committee for Cardiovascular Rehabilitation of the Guangdong Association of Integrated Traditional Chinese and Western Medicine. Shenzhen Chinese medicine Qihuang project leading talents, Shenzhen high-level talents, Shenzhen health elite talents, Guangzhou Pearl River science and technology star talents.
Education
2018.12-2021.09 PostDoc. Traditional Chinese medicine and western medicine. Fujian university of traditional Chinesemedicine, China.
2019.09-2019.10 Professional training. Cardiac rehabilitation management. MAYO CLINIC,，Cardica Rehabilitation Workshop.
2016.10-2016.11 Visiting scholar. CVD (cardiovascular disease).
Centro Cardiologico Monzino
2010.10-2012.01 Visiting scholar. Cardiovascular clinical pharmacodynamics.
State key laboratory of auxiliary circulation, Zhongshan University, China
2009.09-2012.07 M.D. Chinese Internal Medicine. Guangzhou University of Chinese Medicine, Guangzhou, China
2007.09-2009.07 M. Med. Chinese Internal Medicine. Guangzhou University of Chinese Medicine, Guangzhou, China.
2002.09-2007.07 B. Med. Chinese Medicine. Guangzhou University of Chinese Medicine, Guangzhou, China
Publications
1.Xiao Jin, Ling Jin, Bingxin Wu, Danping Xu*. Naringenin protects myocardial ischemia/reperfusion injury through regulating miR-24-3p to inhibit cell death inducing p53 target 1 expression. Gen Physiol Biophys. 2024 Jan;43(1):13-23.
2.Xiaolun Liang, Yuge Xia, Zhirui Xu, Qiang Zeng, Guochuan Gao, Jiangshan He, Danping Xu*. Treatment of diabetic foot ulcers with external application of Chinese herbal medicine: An overview of overlapping systematic reviews. Int Wound J. 2023 Dec 22. doi: 10.1111/iwj.14563.
3.Jin Xiao, W U Bingxin, W U Huanlin, X U Danping*. Effectiveness of Shenshu Guanxin recipe granules for improving exercise tolerance in patients with stable angina pectoris: a randomized, double-blind, placebo-controlled trial. J Tradit Chin Med. 2023, 43(6):1227-1233.
4.Qi Wang, Jiayun Chen, Yezi Zhang, Danping Xu, Huanlin Wu, Pei Lin, Liangliang He, Zifei Qin, Zhihong Yao. Metabolic profile and potential mechanisms of Wendan decoction on coronary heart disease by ultra-high-performance quadrupole time of flight-mass spectrometry combined with network pharmacology analysis. Journal of Separation Science, 2023,46(1):e2200456.
5.Pei Lin, Liufang Hu, Qiaoting Huang, Yezi Zhang, Zifei Qin, Jiaxu Chen, Xinsheng Yao, Huanlin Wu, Zhihong Yao*, Danping Xu*. Pharmacokinetics integrated with network pharmacology to clarify effective components and mechanism of Wendan decoction for the intervention of coronary heart disease. J Ethnopharmacol, 2023,314:116669. doi: 10.1016/j.jep.2023.116669.
6.Guiyu Li, Jiyong Lin, Danping Xu*. Epidemiological Characteristics of COVID-19 and Effective Public Health Interventions in Shenzhen, China. Frontiers in Public Health, 2022(10):923175. WOS:000827287100001
7.Zexuan Wu,?Danping Xu,?Zhen Wu#,?Ailan Chen,?Lijuan Liu,?Li Ling,?Yan Zhou,?Duoduo Liu,?Yin Liu,?Yugang Dong,?Yili Chen. Efficacy of Intensive Treatment vs. Standard Treatment of Compound Danshen Dripping Pills in Refractory Angina Patients With Incomplete Revascularization (INCODER Study): Study Protocol for a Multicenter, Double-Blind, Randomized Controlled, Superiority Trial. Front Cardiovasc Med, 2022, 9:860059 （WOS:000805955700001）
8.XU Dan-ping, XU Jun-peng, HE Zhi-ling, PAN Guang-ming, and WANG Xia*. Correlation between Characteristics of Coronary Plaque and Chinese Medicine Syndromes of Coronary Heart Disease: A Cross-Sectional Study Analysed by Intravascular Ultrasound. Chinese Journal of Integrative Medicine, 2022,28(9):840-846. （WOS:000744408100004）
9.CHEN Benjian, HUANG Xiaodan, PENG Huiting, LI Yishi, CAO Yongtao*, WU Huanlin, XU Danping*. Effectiveness and safety of red yeast rice predominated by monacolin K β-hydroxy acid form for hyperlipidemia treatment and management[J]. Journal of Traditional Chinese Medicine, 2022, 42(2): 264-271.
10.Yi-Ke Lin, Yi-Jun Chen, Jie-Yi Li, Yu-Lin Chen, Dong He, Rui Zuo, Min-Jun Xiao, Dan-Ping Xu, Chao-Yang Zheng, Wei Wang , Rong-Rong He, Yang Chen. Salvianolic acid A from Danhong Injection induces vasorelaxation by Regulating L-type calcium channel in isolated mouse arteries. J Ethnopharmacol., 2022 Oct 5:296:115431.
11.Shujun Xu, Bingxin Wu, Biying Zhong, Luoqi Lin, Yining Ding, Xiao Jin, Zhiwei Huang, Miaoyang Lin, Huanlin Wu, Danping Xu*.Naringenin alleviates myocardial ischemia/reperfusion injury by regulating the nuclear factor-erythroid factor 2-related factor 2 (Nrf2) /System xc-/ glutathione peroxidase 4 (GPX4) axis to inhibit ferroptosis. BIOENGINEERED, 2021, 12(2):10924-10934.
12.Manting Huang, Minzhen Deng, Wenqiang Nie, Dezhi Zou, Huanlin Wu* and Danping Xu*. Naringenin Inhibits Platelet Activation and Arterial Thrombosis Through Inhibition of Phosphoinositide 3-Kinase and Cyclic Nucleotide Signaling. Front Pharmacol, 2021, 12:722257. doi: 10.3389/fphar.2021.722257.
13.Jinhai Lin, Bingxin Wu, Luoqi Lin, Yining Ding, Biying Zhong, Zhiwei Huang, Miaoyang Lin, Dan-Ping Xu*. Effect of aspirin in takotsubo syndrome: protocol of a systematic review and meta-analysis. BMJ Open, 2021, 11(8):e046727. doi: 10.1136/bmjopen-2020-046727.
14.Jinhai Lin,*, Bingxin Wu, Luoqi Lin, Yining Ding, Biying Zhong, Zhiwei Huang, Miaoyang Lin, and Danping Xu*. Understanding the Benefits of Standing and Sitting Baduanjin Based on Cardiopulmonary Exercise Testing: An Observational Study. J Altern Complement Med, 2021 May 6. doi: 10.1089/acm.2020.0458.
15.Qi Wang, Zhenyu Zou, Yezi Zhang, Pei Lin, Taohua Lan, Zifei Qin*, Danping Xu, Huanlin Wu, Zhihong Yao*. Characterization of chemical profile and quantification of major representative components of Wendan decoction, a classical traditional Chinese medicine formula. J Sep Sci. 2021;44:1036–1061.
16.Xuanjing Chen, Dezhi Zou, Xiaoling Chen, Huanlin Wu*, Danping Xu*. Hesperetin inhibits foam cell formation and promotes cholesterol efflux in THP?1?derived macrophages by activating LXRα signal in an AMPK?dependent manner. Journal of Physiology and Biochemistry, 2021, 77(3):405-417.
17.Manting Huan, Huanlin Wu*, Jianping Wu, Qiuxiong Chen, Dezhi Zou, Danping Xu*. Prevention of platelet aggregation and arterial thrombosis using a modified Shenzhu Guanxin Formula. J Int Med Res, 2020, 48(10): p300060520941326.
18.Bingxin Wu, Yining Ding, Biying Zhong, Xiao Jin, Yongtao Cao*, Danping Xu. Intervention Treatment for Myocardial Infarction With Tai Chi: A Systematic Review and Meta-analysis. Arch Phys Med Rehabil. 2020,101(12):2206-2218.
19.Hanqing Liu,?Wei Liu,?Huiliang Qiu,?Dezhi Zou,?Huayang Cai,?Qiuxiong Chen,?Chaoyang Zheng*,?Danping Xu*. Salvianolic acid B protects against myocardial ischaemia-reperfusion injury in rats via inhibiting high mobility group box 1 protein expression through the PI3K/Akt signalling pathway. Naunyn Schmiedebergs Arch Pharmacol, 2020, 393(8):1527-1539.
20.Qiu Huiliang, Liu Wei, Lan Taohua, Pan Wenjun, Chen Xiaoling, Wu Huanlin*, Xu Danping*. Salvianolate reduces atrial fibrillation through suppressing atrial interstitial fibrosis by inhibiting TGF-β1/Smad2/3 and TXNIP/NLRP3 inflammasome signaling pathways in post-MI rats. Phytomedicine, 2018, 51, 255-265.
21.Liu Hongying, Xu Danping, Zhong Xin, Xu Dongsheng, Chen Geng, Ge Junbo*, Li Hua*. LncRNA-mRNA competing endogenous RNA network depicts transcriptional regulation in ischaemia reperfusion injury. J Cell Mol Med, 2019, 23, 2272-2276.
22.Lan Tao-Hua, Xu Dan-Ping, Huang Man-Ting, Song Ju-Xian, Wu Huan-Lin*, Li Min*. Ginsenoside Rb1 prevents homocysteine-induced EPC dysfunction via VEGF/p38MAPK and SDF-1/CXCR4 activation. Sci Rep, 2017, 7:13061.
23.Lan Tao-Hua, Zhang Lu-Lu, Wang Yong-Hua, Wu Huan-Lin*, Xu Dan-Ping*. Systems Pharmacology Dissection of Traditional Chinese Medicine Wen-Dan Decoction for Treatment of Cardiovascular Diseases. EVID-BASED COMPL ALT, 2018, 2018, 5170854.
24.Xu Dan-Ping, Zou De-Zhi, Qiu Hui-Liang, Wu Huan-Lin*. Traditional Chinese Medicine ShenZhuGuanXin Granules Mitigate Cardiac Dysfunction and Promote Myocardium Angiogenesis in Myocardial Infarction Rats by Upregulating PECAM-1/CD31 and VEGF Expression. EVID-BASED COMPL ALT, 2017, 2017, 5261729.
25.Jin Xiao, Pan Biqi, Wu Huanlin, Wu Bingxin, Li Yukai, Wang Xia, Liu Guoqing, Dang Xiaojing, Xu Danping*. The efficacy and safety of Shenzhu Guanxin Recipe Granules for the treatment of patients with coronary artery disease: protocol for a double-blind, randomized controlled trial. Trials, 2019, 20(1): 520.
26.Jin Xiao, Pan Jianke, Wu Huanlin*, Xu Danping*. Are left ventricular ejection fraction and left atrial diameter related to atrial fibrillation recurrence after catheter ablation?: A meta-analysis. Medicine (Baltimore),2018, 97, e10822.
27.Jin Xiao., Pan Biqi., Dang Xiaojing., Wu Huanlin.*, Xu Danping*. Relationship between short telomere length and stroke: A meta-analysis. Medicine (Baltimore), 2018, 97, e12489.
28.Jin Xiao, Pan BiQi, Wu Huanlin*, Xu Danping*. The effects of traditional Chinese exercise on hypertension: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore), 2019, 98, e14049.
29.Xu Dan-Ping, Wu Huan-Lin*, Lan Tao-Hua, Wang Xia, Sheng Xiao-Gang, Lin Yu, Li Song, Zheng Chao-Yang. Effect of Shenzhu Guanxin Recipe on patients with angina pectoris after percutaneous coronary intervention: A prospective, randomized controlled trial. Chin J Integr Med, 2015, 21, 408-16.
30.Wang Lanhua, Xu Danping, Liu Bin, Jin Ling, Wang Decai, He Mingguang, Congdon Nathan G, Huang Wenyong. Novel system for distant assessment of cataract surgical quality in rural China. Clin Exp Ophthalmol, 2015,43(7): 621-628.
31.Huang Manting,Wu Huanlin*, Xu Dan-Ping*. In vitro study of naringenin antagonizing platelet aggregation through PI3K/Akt pathway. [J] .Chinese Journal of Pathophysiology, 2017, 33(3): 517-522.
32.Huang Manting,Wu Huanlin, Xu Dan-Ping. In vitro Study of Naringenin Against Platelet Aggregation Through Cyclic Nucleotide Pathway. [J] .Chinese Journal of Pathophysiology, 2017, 33(7): 1306-1312.
33.Huang Manting,Wu Huanlin,Xu Dan-Ping. On Antiplatelet Aggregation and Structure-activity Relationship of Citrus flavone. [J]. New Chinese Medicine and Clinical Pharmacology, 2017, 28(3).
34.Mao Shuai, Xu Dan-Ping, Dang Xiao-Jing, Li Winny, Wu Huan-Lin*. Shenzhu Guanxin Recipe Granules for Improving Exercise Tolerance in Patients with Stable Angina (SERIES Trial): A Protocol of Multicenter, Randomized, Double-Blind, Placebo Parallel Controlled Clinical Trial. Chin J Integr Med, 2019, 25, 96-102.
35.Cai Huayang, Li Hui, Zeng Huizhen, Xu Danping, Ouyang Wenwei, Lv Aiping. Application evaluation of clinical practice guidelines for traditional Chinese medicine: a clinical analysis based on the analytic hierarchy process. BMC Complem Altern M, 2019, 19, 277.
36.Yin Chunxia, Chen Yaoxu, Wu Huanlin, Xu Danping, Tan Wen. Attenuation of ischemia/reperfusion-induced inhibition of the rapid component of delayed rectifier potassium current by Isosteviol through scavenging reactive oxygen species. Biochim Biophys Acta Biomembr, 2017, 1859, 2447-2453.
37.Lan Tao-Hua, Chen Xiao-Ling, Wu Yun-Shan, Qiu Hui-Liang, Li Jun-Zhe, Ruan Xin-Min, Xu Dan-Ping, Lin Dong-Qun. 3,7-Bis(2-hydroxyethyl)icaritin, a potent inhibitor of phosphodiesterase-5, prevents monocrotaline-induced pulmonary arterial hypertension via NO/cGMP activation in rats. Eur J Pharmacol, 2018, 829, 102-111.
38.Xu Danping, Lu Weihui, Ma Liuling, Wu Jianping,(2014). Evaluation of the clinical guidelines for the management of angina pectoris with traditional Chinese medicine in multi-level hospitals, Bioinformatics and Biomedicine (BIBM), 2014 IEEE International Conference, 182–186.
39.Xu Danping, Wang Xia, Luo Wenjie, et al, (2014). The clinical cohort study on prospective efficacy of CHD Therapeutic Regimen of “the regulation of Pi(Spleen) and protection of Xin(Heart)” method treating CHD patients. Bioinformatics and Biomedicine (BIBM), 2014 IEEE International Conference , 179 – 181.
40. LIN Miao-yang, LIN Luo-qi, WU Bing-xin, et al. Efficacy of Kuanxiong Aerosol on Exercise Capacity in Coronary Heart Disease Angina PectorisPatients[J]. Chinese Journal of Integrated Traditional and Western Medicine, 2023(6): 653-657.
41. XU Dan-ping, WU Bing-xin, LI Qian, et al. Clinical Study of Kuanxiong Aerosol’s Efficacy on Exercise Tolerance of Patients with Coronary Heart Disease Complicated with Chest Tightness / Pain after Activities[J]. Chinese Journal of Integrated Traditional and Western Medicine, 2020(3): 287-289.
42. CHEN Xuan-jing, XU Dan-ping, CHEN Xiao-guang, et al. Overview of the relationship between phlegm syndrome and objective indexes incoronary heart disease[J]. China Journal of Traditional Chinese Medicine and Pharmacy, 2017(7): 3089-3092.
43. PENG Hui-ting, CHEN Zi-yue, LI Yi-shi, et al. Study on essence of six meridians in Shanghan Lun through symbol of three yin and three yang[J]. China Journal of Traditional Chinese Medicine and Pharmacy, 2018(8): 3249-3252
44. Zou Dezhi, Guo Mingming, Liu Jianghui, et al. Impact of purinergic receptor P2Y12 gene inhibited by siRNA on the angiogenesis of hepatocellularcarcinoma[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2015(1): 53-56.
?
